Press Releases Year None2024202320222021202020192018 Dec 03, 2024 Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants Nov 12, 2024 Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs Nov 05, 2024 Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update Sep 11, 2024 Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference Sep 06, 2024 Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Sep 04, 2024 Vaxcyte Announces Pricing of $1.3 Billion Public Offering Sep 03, 2024 Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants Sep 03, 2024 Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older Sep 02, 2024 Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older Aug 06, 2024 Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 23
Year None2024202320222021202020192018 Dec 03, 2024 Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants Nov 12, 2024 Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs Nov 05, 2024 Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update Sep 11, 2024 Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference Sep 06, 2024 Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares Sep 04, 2024 Vaxcyte Announces Pricing of $1.3 Billion Public Offering Sep 03, 2024 Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants Sep 03, 2024 Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older Sep 02, 2024 Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older Aug 06, 2024 Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 23
